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http://dx.doi.org/10.1016/j.ccr.2013.02.026SUMMARYWe isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody
library, using a pioneering ‘‘function-first’’ approach involving screening for (1) specificity for a tumor B cell
surface receptor, (2) induction of tumor programmed cell death, and (3) enhanced in vivo antitumor activity
compared to currently used treatments. BI-505 bound to intercellular adhesion molecule-1, identifying
a previously unrecognized role for this receptor as a therapeutic target in cancer. The BI-505 epitope was
strongly expressed on the surface of multiple myeloma cells from both newly diagnosed and relapsed
patients. BI-505 had potent macrophage-dependent antimyeloma activity and conferred enhanced survival
compared to currently used treatments in advanced experimental models of multiple myeloma.INTRODUCTION
Targeted immunotherapy plays an increasingly important role in
the treatment of cancer (Weiner et al., 2010). Still, antibodies with
antitumor activity have yet to be generated for several types of
cancer, and a significant proportion of patients who initially
respond to the currently available therapies develop resistance
(Smith, 2003). The search for antitumor antibodies is thus critical
for the further development of targeted immunotherapy.
A common first step of conventional antibody discovery
approaches is to isolate antibodies with specificity for a prede-
fined target structure, which may be previously uncharacterized
or well validated with respect to cancer therapy. Therapeutic
efficacy is not, however, easily predicted from antibody targetSignificance
Antibody therapy plays a growing role in the treatment of canc
ing ligand-receptor signaling pathways and/or by triggering of a
in vivo antimyeloma activity of an antibody isolated by ta
Mechanism-of-action studies demonstrated that the antibody i
phage-dependent host antitumor immunity in a manner that w
mation on the receptor targeted by the antibody. Our results
predefined target approaches to broaden therapeutic target s
502 Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc.specificity; antibodies to the same target receptor may vary
greatly in therapeutic efficacy independent of their binding
affinity (Beers et al., 2008; Cragg and Glennie, 2004), and anti-
bodies against alternative molecular targets may show prom-
ising, and sometimes unexpected, therapeutic potential (Beck
et al., 2010; Cheson and Leonard, 2008). It is therefore important
to use a ‘‘function-first,’’ rather than a target specificity-based,
approach to therapeutic antibody discovery.
We have developed an approach that allows screening of
large numbers of antibodies for useful antitumor activity without
prior identification of the target receptors (Fransson et al., 2006).
This high-throughput, function-first approach allows rapid
identification of candidates that display key properties for an
antitumor antibody, e.g., specificity for differentially expresseder. Antibodies may exert their therapeutic function by target-
ntibody-unique effector functions. Here, we describe potent
rget-unbiased functional screening for tumor cell death.
nduced apoptosis in target tumor cells and activatedmacro-
ould not have been predicted from currently available infor-
help illustrate how functional screening may complement
pace by discovering functions of known targets.
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ICAM-1 Antibody Has In Vivo Antimyeloma Activitytumor cell surface receptors, significant ability to confer pro-
grammed cell death (PCD) in tumors, and significant antitumor
activity in vivo compared to currently used treatments.
When applied to find antibodies with improved antitumor
activity against B cell malignancies, the process identified
several tumor PCD-inducing antibodies—specific for different
tumor B-cell-associated receptors—that showed better anti-
tumor activity compared to rituximab, a CD20-specific mono-
clonal antibody used for treatment of CD20-expressing B cell
cancers (Fransson et al., 2006).
Interestingly, among antibodies identified were several spe-
cific for intercellular adhesion molecule 1 (ICAM-1), a receptor
not previously associated with tumor PCD. ICAM-1 is highly ex-
pressed in several human malignancies and is believed to be
involved in their pathogenesis (Aalinkeel et al., 2004; Hideshima
et al., 2007; Huang et al., 1995; Johnson et al., 1988; Schmidma-
ier et al., 2006). Notably, ICAM-1 was recently reported to be
overexpressed and associated with advanced disease and
poor survival in multiple myeloma (MM) (Sampaio et al., 2009;
Schmidmaier et al., 2006). Further, evidence suggests that
ICAM-1 is upregulated and causally related to MMpatient devel-
opment of resistance to chemotherapy (Sampaio et al., 2009;
Schmidmaier et al., 2006; Zheng et al., 2009). ICAM-1, by bind-
ing to integrin b2 receptors and muc-1, is involved in cell-
adhesive events that trigger multiple cell-signaling pathways
promoting MM cell proliferation, migration, resistance to apo-
ptosis, and development of cell adhesion molecule-induced
drug resistance (Hideshima et al., 2007; Schmidmaier et al.,
2004; Zheng et al., 2009). There is no curative treatment for
MM, and the currently available therapy is associated with signif-
icant toxicity and development of drug resistance (Kyle and
Rajkumar, 2004). MM plasma cells typically do not express the
B cell antigen CD20 or show low and heterogeneous CD20
expression, making CD20-targeted therapies ineffective in this
disease (Kapoor et al., 2008; Richardson et al., 2011).
Here, we characterize MM plasma cells for expression of the
ICAM-1 epitope targeted by our function-first-isolated antibody
BI-505, and we investigate BI-505’s therapeutic activity and
mechanism-of-action in well-established experimental models
of MM.
RESULTS
A Human ICAM-1 Antibody Isolated by a Function-First
Approach Has Significant Antitumor Activity against
B Cell Cancer Xenografts
We isolated multiple antibodies inducing programmed cell death
(PCD) in B cell lymphomas, targeting different tumor-cell-
associated surface receptors, by means of a sequential process
involving differential biopanning and high-throughput PCD
screening of antibodies from the n-CoDeR (So¨derlind et al.,
2000) human antibody library (Figures S1A–S1C available
online). The high specificity for ICAM-1 of one of these anti-
bodies, BI-505 (appears as B11 in Fransson et al., 2006), is
shown in Figure S1C. BI-505 dose-dependently induced PCD
in ICAM-1-expressing Ramos, Raji, and Daudi lymphoma cells
(Fransson et al., 2006; Figure 2D).
In order to further investigate the therapeutic potential of PCD-
inducing ICAM-1 antibodies, we screened BI-505 for in vivo anti-tumor activity in tumor models comprising SCID mice trans-
planted with the lymphoblastic cell lines ARH-77 or Daudi.
Both cell lines express the CD20 antigen, making it possible to
compare antitumor efficacy and potency of antibodies identified
here with those of the clinically validated CD20-specific mono-
clonal antibody rituximab.
Subcutaneous injection of ARH-77 cells resulted in rapid
establishment and growth in SCID mice, with tumors being
readily palpable between 12 and 14 days. Twice-weekly injec-
tions of 20 mg/kg of BI-505 commencing 1 day after tumor cell
inoculation prevented tumor growth in 9 out of 10 injected mice
(Figure 1A). Rituximab conferred significant antitumor activity
at the samedosebutwas less efficacious thanBI-505 (Figure 1A).
Furthermore, BI-505 administered at a 100 times lower dose
(0.2 mg/kg) was equally efficacious compared to 20 mg/kg ritux-
imab in conferring survival (Figure 1B). The high efficacy and po-
tency of BI-505 was confirmed in mice carrying ARH-77 tumors
established for 12 days before the start of antibody treatment
(Figures 1C and 1D). In this model, rituximab failed to reduce
tumor growth or promote animal survival (p > 0.05), whereas
BI-505 both significantly reduced tumor growth (Figure 1C;
p < 0.05) and prolonged animal survival (Figure 1D; p < 0.05).
Thus, in this aggressive model of CD20-positive B cell malig-
nancy, BI-505 was more efficacious and more potent in con-
ferring antitumor activity and survival than rituximab.
We also tested BI-505’s antitumor activity against Daudi B cell
lymphoma xenografts. Again, BI-505 significantly prevented
tumor growth (Figures 1E and 1G; p < 0.001) and prolonged sur-
vival (Figures 1F and 1H; p < 0.001) of tumor-bearing mice when
administered 1 day following tumor cell injection (Figures 1E
and 1F) or when established tumors were treated (Figures 1G
and 1H), this timewith equal efficacy compared to rituximab (Fig-
ures 1E–1H). The overall stronger antitumor activity of BI-505
compared with rituximab was not caused by a higher number
of tumor cell epitopes for BI-505 than for rituximab. In contrast,
flow cytometric analysis revealed that both ARH-77 (Figure 1I)
and Daudi (Figure 1J) cells expressed significantly fewer BI-
505 epitopes than rituximab epitopes, and immunohistochem-
ical analysis of tumor tissue harvested from mice treated with
BI-505, rituximab, or isotype control antibodies showed that
tumors expressed both rituximab and BI-505 epitopes at the
completion of experimentation (Figure S1D).
To establish the potency of BI-505 in vivo and the lowest dose
achieving maximal antitumor activity, we performed a dose-
titration experiment using the SCID/ARH-77 model system. BI-
505 showed dose-dependent antitumor activity, which followed
a sigmoidal curve, peaking at the 2 mg/kg dose and remaining
near maximal at a dose of 0.2 mg/kg (Figures 2A and 2B). Anti-
body concentrations in mouse sera were determined by ELISA
and were plotted as a function of maximal in vivo antitumor
activity (Figure 2C). The relationship between BI-505 concentra-
tion-dependent in vivo antitumor activity, in vitro antitumor (PCD)
activity (Figure 2D), and in vitro receptor occupancy (Figure 2E)
was then examined by overlaying generated curves in a single
graph (Figure 2F). BI-505 concentration-dependent receptor
occupancy correlated nearly perfectly with BI-505 in vitro and
in vivo antitumor activity (Figure 2F). This result is consistent
with ICAM-1-dependent direct cell cytotoxicity underlying
BI-505’s antitumor activity.Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc. 503
Figure 1. BI-505 Has Significant In Vivo Antitumor Activity against CD20-Expressing Tumors Compared with Rituximab
(A–H)Mean tumor volumes (A, C, E, andG) and survival (B, D, F, andH) ofmice xenograftedwithCD20-expressingARH-77 (A–D) orDaudi (E–H) cells and treatedwith
BI-505 (bright red line = 20 mg/kg BI-505; maroon line = 2 mg/kg BI-505; and orange line = 0.2 mg/kg BI-505), rituximab (20 mg/kg, blue line), or isotype control
(20mg/kg,black line) antibodies inprophylactic (A,B,E,andF)orestablished (C,D,G,andH) tumormodels. Therewereeight to tenanimalsper treatment/dosegroup.
Tumor cells were injected day 0, and antibody treatment started as indicated in the graphs (black arrow). *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars show± SD.
(I and J) FACS analysis of BI-505 and rituximab epitopes on the surface of ARH-77 (I) and Daudi (J) tumor cells. Antibodies were used at binding saturating
concentrations.
See also Figure S1.
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ICAM-1 Antibody Has In Vivo Antimyeloma ActivityWe conclude that BI-505 confers potent and direct antitumor
activity against different types of B cell cancer.
ICAM-1 and the BI-505 Epitope Are Strongly Expressed
in Multiple Myeloma
We next evaluated expression of the BI-505 epitope on bone
marrow cells in patients with MM and related diseases (plas-
macytoma, plasma cell leukemia, and light-chain amyloidosis)
by flow cytometry (Figure 3; Table 1). Myeloma cells were
identified using fluorescent antibodies against surface antigens
CD38, CD138, CD45, and CD56 (Figure S2A), according to the
European Myeloma Network guidelines on multiparametric
flow cytometry in MM (Rawstron et al., 2008) and confirming504 Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc.monoclonal MM cells with intracellular staining of l and k light
chains. All MM patients expressed the BI-505 epitope on most
(97% ± 4%, mean ± SD, patient n = 22) myeloma cells (Fig-
ure 3; Table 1). The BI-505 epitope was generally very highly
expressed on these cells, with a median expression level
that was ten times higher than on normal B cells from the
same patients. Similar results were obtained with a commer-
cially available anti-ICAM-1 antibody (data not shown). Further-
more, the BI-505 epitope was highly expressed on myeloma
cells in a patient in relapse who had received several different
lines of therapy (Figure S2B). Thus, ICAM-1 and the BI-505
epitope are strongly expressed on the surface of MM plasma
cells.
Figure 2. BI-505 Dose-Dependent Anti-
tumor Activity Correlates with ICAM-1 Re-
ceptor Occupancy on Tumor Cell Surfaces
(A and B) Mean tumor volumes (A) and mean sur-
vival (B) of mice treated with different doses of
BI-505 in the ARH-77 tumor model. Error bars
show ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001.
(C–E) BI-505 concentration-dependent in vivo
antitumor activity (C), in vitro antitumor (tumor
PCD) activity (D), and receptor occupancy of tumor
cell-expressed ICAM-1 (E).
(F) A combined plot of (C)–(E). There were eight to
ten animals per treatment group.
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ICAM-1 Antibody Has In Vivo Antimyeloma ActivityBI-505 Has Broad Antimyeloma Activity In Vivo
Because we found high expression of the BI-505 epitope in
human MM, we proceeded to screen BI-505 for in vivo antimye-
loma activity using SCID/xenograft models comprising four
well-characterized MM cell-lines. These cell lines express the
myeloma markers CD38 and CD138 but do not express CD20.
Twice-weekly dosing with 2 mg/kg of BI-505 starting 1 day after
tumor cell injection reduced myeloma tumor growth in mice
xenografted with ICAM-1-expressing cell lines EJM, RPMI-
8226, and NCI-H929 by 98%, 96%, and 99%, respectively (Fig-
ures 4A and 4B). In contrast, BI-505 did not affect tumor growth
in mice xenografted with the ICAM-1-negative cell line OPM-2
(Figures 4A and 4B). Taken together, these studies indicated
that BI-505 had highly efficacious, broad, and ICAM-1-depen-
dent in vivo antimyeloma activity.Cancer Cell 23, 502–5BI-505 Has Potent Antimyeloma
Activity in Clinically Relevant
Models of Advanced Myeloma
To assess the therapeutic potential of
BI-505 for treatment ofMM,we next com-
pared the antimyeloma effects of BI-505
to current gold-standard treatment in
disseminated experimental models of
MM sharing characteristics with human
disease. These models resemble the
manifestation and progression of human
MM disease in many respects, including
tumor dissemination and establishment
in bone marrow, and the appearance of
osteolytic bone lesions and hypercalce-
mia (Mitsiades et al., 2003; Yaccoby
et al., 1998). First, we compared the anti-
myeloma activity of BI-505 with currently
used treatments in an advanced dissemi-
nated MM model comprising RPMI-8226
myeloma cells. In this model, therapeutic
treatment with 2 mg/kg BI-505 was
started 5 days after intravenous grafting
of MM cells to allow for homing and
establishment of MM cells in bone
marrow. BI-505 significantly enhanced
survival and delayed disease onset
compared to treatment with the com-
parator drugs bortezomib, lenalido-
mide, melphalan, or dexamethasone (Fig-ure 5A), all approved and currently used for MM therapy.
Importantly, Figure 5A shows the effect of the comparator drugs
used at maximally efficacious, and clinically relevant, doses.
Higher doses of some of the comparator drugs were shown to
be toxic, but not more efficacious, to animals (data not shown).
Primary human MM cells depend on interactions with bone
marrow stromal cells to proliferate and survive. The SCID-hu
mouse harbors a human microenvironment, where primary pa-
tient MM cells proliferate and induce pathology similar to human
clinical MM (Yaccoby et al., 1998). MM-cell-derived human
immunoglobulin G (IgG) titers were detected (>10 mg/ml) in the
serum of SCID-hu mice 4 weeks after implantation of human
MM cells to transplanted human bones, at which time treatment
with antibodies (2 mg/kg) or bortezomib (1 mg/kg) began.
Human IgG titers increased steadily in control-treated SCID-hu15, April 15, 2013 ª2013 Elsevier Inc. 505
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Figure 3. The BI-505 Epitope Is Highly
Expressed on the Surface of Primary MM
Plasma Cells
FACS analysis of BI-505 epitope expression on the
cell surface of patients’ MM cells (red bars) versus
normal B cells (yellow bars). Numbers on top of
bars indicate fold increase of the BI-505 epitope on
surface of MM cells compared to normal B cells.
Patient numbers correspond to those shown in
Table 1.
See also Figure S2.
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ICAM-1 Antibody Has In Vivo Antimyeloma Activitymice over the course of experimentation to reach maximal con-
centrations of 40 ± 5 mg/ml just before sacrifice (Figures 5B and
S3). In contrast, therapeutic treatment with BI-505 or bortezomib
halted or reduced serum human IgG levels to below pre-
treatment levels (hIgGBI-505 = 91% ± 22%), demonstrating a
significant anti-MM effect. Two independent experiments were
performed with similar results (Figures 5B and S3), each with
MM cells from two different patient donors (n = 4). Immunohis-
tochemical staining for human CD138-expressing cells in har-
vested human bone implants indicated that BI-505 antimyeloma
effects correlated with decreased tumor burden (Figure 5C).
BI-505 antimyeloma effects correlated with protection against
MM-induced bone pathology as demonstrated by decreased
bone remodeling with decreased loss of bone mineral density
(Figure 5D). Staining of a limited number of bone sections indi-
cated reduced numbers of bone osteoclasts (Figure 5E) and total
infiltrated nucleated cells (Figure 5F) in BI-505- or bortezomib-
treated mice compared to control-treated mice.
Thus, in two clinically relevant experimental models BI-505
anti-MM activity was equal to or greater than currently available
drugs.
BI-505 Confers Fc-FcgR-Dependent Antitumor Activity
through Macrophages
Previous studies have demonstrated PCD-inducing properties of
BI-505 in a wide range of tumor B cell lines (Fransson et al.,
2006). BI-505 PCD was enhanced by antibody crosslinking
in vitro, indicating that in vivo antitumor activity might be
enhanced by crosslinking provided by FcgR-expressing cells
(Wilson et al., 2011). Given the critical importance of FcgR-
mediated antitumor mechanisms for the clinical and in vivo ther-
apeutic activity of clinically validated cancer mAbs (Clynes et al.,
2000; Musolino et al., 2008; Weng and Levy, 2003), we ad-
dressed the contribution of antibody Fc: host FcgR-dependent
mechanisms for BI-505’s therapeutic activity. To this end, we
engineered BI-505 variants with abolished (IgG1 N297Q, ‘‘Fc-
mut’’), or reduced (BI-505-IgG4) FcgR-binding compared to
wild-type BI-505 IgG1, and investigated their respective in vivo
therapeutic activities. The Fc-switch variants retained affinities
for ICAM-1 as evidenced by near identical EC50 values for bind-
ing to recombinant or cell-surface-expressed ICAM-1 (Figures
S4A–S4C). The in vivo antitumor activity of BI-505 Fc-variants
(Figure 6A) correlated perfectly with binding to mouse FcgRIV
(Figure 6B)—the structural and functional homolog of human
FcgRIIIa and a principal murine FcgR conferring antibody-506 Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc.mediated cell cytotoxicity in vivo (Nimmerjahn et al., 2005)—
increasing in the order of IgG1 N297Q < IgG4 < IgG1. Importantly,
mice treated with IgG1, IgG4, and IgG1 N297Q variant antibodies of
BI-505 had similar serum antibody titers at the end of experimen-
tation, indicating that the different antibody variants had similar
in vivo half-lives and demonstrating that differential antitumor
activity did not result from differential pharmacokinetics
(Table S1). These findings demonstrated that BI-505 in vivo anti-
tumor activity was Fc: FcgR-dependent.
Fc-FcgR-interactions, in addition to enhancing antibody-
induced negative signaling and tumor PCD (Wilson et al.,
2011), may involve both innate and adaptive arms of cellular
immunity (Alduaij and Illidge, 2011; Park et al., 2010). We used
different approaches to assess the role of NK cells and
macrophages—two principal cell types capable of conferring
FcgR-dependent antitumor effects—for BI-505 therapeutic
activity. First, we examined the relative abundance of these
cell types in tumor tissue harvested from BI-505 or control-
antibody-treated mice. By immunohistochemistry, we found
that macrophages (F4/80+ cells) constituted the vast majority
of FcgR-expressing cells in BI-505-treated tumors (Figure 6D).
In contrast, very few intratumoral NK cells could be detected
(CD49b+ CD31 cells). Furthermore, and interestingly, treatment
with BI-505 significantly increased tumormacrophage infiltration
but—conversely—decreased tumor NK cell content (Figure 6D).
Together, these data suggested that macrophages, but not NK
cells, were principal FcgR-expressing cells conferring BI-505
antitumor activity in vivo. To verify this, we depleted macro-
phages or NK cells, using clodronate liposomes and anti-asialo
antibodies, respectively, from SCID mice bearing established
RPMI-8226 myeloma tumors and examined the effect on
BI-505 antimyeloma activity. A period of 3 weeks of macrophage
and NK cell depletion was chosen as readout because this was
the longest time period in which neither treatment affected
animal well-being. Cell depletion did not per se impact tumor
growth over this period of time (Figures S4D and S4E). Figure 6E
clearly demonstrates that macrophage depletion completely
abolished BI-505 in vivo antitumor activity. Tumors of macro-
phage depleted BI-505-treated mice had doubled in size
compared with tumors from animals receiving BI-505 treatment
alone (VBI-505 = 95 ± 39 mm
3, VBI-505+clodro = 189 ± 94 mm
3,
p < 0.001) but were similarly sized compared to tumors from
control-antibody-treated mice (Vctrl IgG = 198 ± 90 mm
3, p >
0.05). NK cell depletion, in contrast, had little or no effect on
BI-505 antitumor activity. Tumor volumes of NK-cell-depleted
Table 1. Expression of the BI-505 Epitope in a Cohort of 29 Patients with Plasma Cell Disorders
Patient Characteristics BI-505 Epitope Expression
Patient
Numbera Age (year) Sexb Igc M- comp (g/l) Skel. Destd (n) MM Cellse (%) ISSf Tg (n) Diagnosish Intensityi Positive Cells (%)
1 38 m IgG 10 0 14 I 0 MM +++ 98
2 46 m IgG 38 0 34 II 0 MM +++ 97
3 53 f IgG 14 >10 6 I 0 MM +++/++ 100
4 54 m – – 3 22 III 2 nsMM +++ 100
5 59 m IgG 32 >10 29 I 0 MM ++ 100
6 60 f IgG 4 3 2 II 1 MM +++ 98
7 60 f IgA 26 1 10 I 0 MM +++ 98
8 61 m IgG 28 0 23 II 0 MM +++ 100
9 62 m IgG 69 >10 30 II 0 MM ++ 100
10 62 f IgG 70 >10 80 III 1 MM + 95
11 68 m IgA 36 >10 60 I 0 MM +++ 100
12 69 m – – 3 50 I 1 nsMM +++/+ 95
13 71 m IgG 26 0 30 I 0 MM +++ 100
14 72 m IgG 13 0 29 I 0 MM +++ 100
15 74 m IgG 20 0 23 I 0 MM +++ 100
16 75 m IgA 40 0 78 II 0 MM ++ 88
17 77 m IgG 45 0 34 II 0 MM +++ 100
18 79 f IgG 23 0 16 I 0 MM +++ 100
19:1 79 m IgG 24 7 50 III 0 MM +++ 93
19:2 79 m IgG 3 n/a n/a – 1 MM +++ 95
19:3 80 m IgG 3 n/a 16 – 2 MM +++ 91
20 82 m IgA 29 0 44 III 0 MM +++ 100
21 83 f IgG 39 0 89 III 0 MM +++ 93
22 84 m IgA 17 0 38 III 0 MM +++ 86
23 61 m IgA 7 2 24 – 0 AL ++ 97
24 64 f – – n/a 6 – 0 AL +++ 100
25 72 f – – 0 1 – 0 LCDD/MM +++ 98
26 61 f IgA 42 n/a 80 – 4 PCL +++ 76
27 75 m IgG 18 >10 8 – 4 PCL + 77
28 52 m IgG 1 1 5 – 1 PC +++ 93
29 60 f IgG 4 1 2 – 1 PC +++ 100
n/a, not analyzed.
aCorresponds to number found in Figure 3.
bm, male; f, female.
cImmunoglobulin class of M-component.
dNumber of skeletal destructions.
eMultiple myeloma cells counted as percent of all nucleated cells in bone marrow smears.
fInternational Staging System of MM.
gNumber of different MM treatment regimens before BI-505 analysis.
hMM,multiple myeloma; nsMM, nonsecretory multiple myeloma; AL, amyloid light-chain amyloidosis; LCDD, light-chain deposit disease; PCL, plasma
cell leukemia; PC, plasmacytoma.
iMeasured by FACS on MM cells. Two patients (no. 3 and 12) had two MM cell populations with differential BI-505 expression.
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ICAM-1 Antibody Has In Vivo Antimyeloma ActivityBI-505-treated mice were not significantly different from mice
treated with BI-505 only (VBI-505 = 95 ± 39 mm
3, VBI-505+asialo =
130 ± 53 mm3, p > 0.05) but were significantly smaller compared
to control-antibody-treated animals (p < 0.01, Figure 6E). BI-505
also had significant antitumor activity in two different aggres-
sively growing NK-cell-deficient MM mouse models comprising
RPMI-8226 or U266 cells grafted to NOD/Shi-scid/IL-2Rg/mice (Figures 6F and 6G). Taken together, our data identify
macrophages, but not NK cells, as critical effector cells confer-
ring BI-505 FcgR-dependent in vivo antitumor activity.
We next investigated BI-505’s ability to mediate Fc:FcgR-
dependent macrophage phagocytosis (antibody-dependent
cell phagocytosis [ADCP]) of human MM cells in vitro. As ex-
pected, BI-505 IgG1 bound to human FcgR (Figure 6C) andCancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc. 507
Figure 4. BI-505 Has Broad and ICAM-1-
Dependent Anti-MM Activity In Vivo
(A) Tumor volume (mean ± SD) of NCI-H929
(ICAM-1+), EJM (ICAM-1+), RPMI-8226 (ICAM-1+),
and OPM-2 (ICAM-1) MMmodels after treatment
with 2 mg/kg BI-505 (filled circles) or control (open
circles) antibody.
(B) Relative tumor volumes following treatment
with 2 mg/kg BI-505 (filled bars) or control (open
bars) antibody in NCI-H929, EJM, RPMI-8226, and
OPM-2 MM models. Graph shows tumor volumes
(mean ± SD) relative to the mean tumor volume
of control IgG-treated animals. There were eight
animals per treatment group.
**p < 0.01, ***p < 0.001; ns, not statistically
different.
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ICAM-1 Antibody Has In Vivo Antimyeloma Activityconferred ADCP of both RPMI-8226 and primary patient’s MM
cells (Figures 6H and 6I) in the presence of humanmacrophages.
In contrast, FcgR-binding-deficient BI-505 IgG1N297Q did not
bind to human FcgR (Figure 6C) and did not confer ADCP of
targeted MM cells (Figures 6H–6J). Similarly, preincubation
with recombinant-soluble Fc gamma receptor diminished BI-
505 IgG1-mediated ADCP (Figure 6J). Therefore, analogous to
the in vivo setting, BI-505-mediated ADCP in vitro was Fc: Fc
gamma receptor dependent.
We also examined the ability of BI-505 to mediate antibody-
dependent cell cytotoxicity (ADCC) against human target tumor
cells in the presence of human effector NK cells. BI-505 con-
ferred cytotoxicity in an Fc-dependent manner, although ADCC
activity by effector NK cells was less pronounced compared
with macrophage-mediated ADCP (data not shown).
Besides Fc:FcgR-dependent antitumor mechanisms, cancer
mAb Fc-dependent antitumor activity may result from activation508 Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc.of the complement cascade by comple-
ment-dependent cytotoxicity (CDC). We
therefore examined the ability of BI-505
to induce CDC in a panel of ICAM-1-
expressing tumor cell lines. However,
BI-505 did not induce CDC in any of the
tumor cell lines monitored (data not
shown). In contrast, treatment with the
positive control rituximab effectively
induced CDC, as has previously been
reported (Cragg and Glennie, 2004;
Cragg et al., 2003; Manches et al., 2003).
In summary, our data provide strong
evidence for Fc:FcgR-dependent anti-
tumor mechanisms, e.g., macrophage-
mediated ADCP and FcgR cross-linking-
induced antibody tumor PCD underlying
BI-505’s therapeutic activity.
Safety Profile of the BI-505
Antibody
In addition to exerting significant anti-
tumor activity, a therapeutic cancer
antibody must be safe and tolerable for
patients. Toxicology studies in relevantanimal species may provide important information on drug
safety. BI-505 does not, however, cross-react with ICAM-1
from animals that are commonly used for toxicological evalua-
tion (data not shown). Our nonclinical safety assessment there-
fore focused on evaluating its effects on viability and function
of human normal (untransformed) cells expressing ICAM-1.
Based on BI-505’s documented ability to confer Fc:FcgR-
dependent antitumor activity in malignant B cells, and a pro-
posed general negative role for complement activation with
regard to antibody tolerability (Lim et al., 2010; van der Kolk
et al., 2001), we examined direct cytotoxic effects (PCD,
ADCC, andCDC) of BI-505 in ICAM-1-expressing human periph-
eral blood B cells and endothelial cells. Whereas peripheral
blood B cells and naive B cells show low endogenous expression
of the BI-505 epitope (Fransson et al., 2006), human umbilical
vascular endothelial cells (HUVECs) and human microvascular
endothelial cells (HMVECs) cells showed significant ICAM-1
Figure 5. BI-505 Confers Enhanced Survival
Compared to Currently Used Treatments in
Disseminated Experimental Models of
Advanced MM
(A) Animal survival in advanced disseminated
RPMI-8226 myeloma model following treatment
with control antibody, lenalidomide, bortezomib,
dexamethasone (DXH), melphalan, or BI-505.
***p < 0.001.
(B) Human immunoglobulin G (hIgG) (mean ± SD) in
SCID-hu mice after myeloma cell inoculation and
drug treatment. Graph shows pooled data from two
independent experiments, each with MM cells
obtained from two different patient donors (n = 4).
The percentage of hIgG levels compared to start of
treatment (arrow) was monitored. ***p < 0.001.
(C) Myeloma tumor burden in implanted bones
harvested from drug-treated mice. Pictures show
representative images of tumor burden as assessed
by immunohistochemistry following staining for
human CD138-expressing cells. Arrows indicate
human CD138-positive myeloma cell regions. Scale
bar = 50 mm.
(D) X-radiographic quantification of bone mineral
density. Radiographs of implanted human bones
receiving drug or control treatment were harvested
from mice at end of experimentation (10 weeks
postmyeloma cell injection and following 6 weeks of
drug treatment). Upper panel shows representative
radiographs of bones from healthy mice, control
IgG-treated mice, BI-505-treated mice, or bortezo-
mib-treated mice (left to right). Lower panel shows
mean ± SD bone mineral density of mice receiving
treatment as indicated. *p < 0.05.
(E and F) Representative images of trap staining
(purple stain) for detection of osteoclasts (E) or
hematoxylin and eosin staining for detection of
infiltrated nucleated cells (F) performed on healthy
and MM cell-injected bones harvested from SCID-
hu mice treated as indicated at end of experimen-
tation. Scale bar = 100 mm.
See also Figure S3.
Cancer Cell
ICAM-1 Antibody Has In Vivo Antimyeloma Activityexpression, which was further upregulated in response to IFN-g
stimulation as determined by flow cytometric analyses (Fig-
ure S5). However, BI-505 did not induce cell death in any of
the resting or activated normal ICAM-1-expressing cell types
that were examined, regardless of whether or not antibody was
crosslinked to mimick Fc:FcgR-crosslinking in vivo (Figures
7A–7C and 7G). In contrast, treatment of endothelial cells with
paclitaxel and treatment of B cells with positive control anti-
HLA-DR or anti-CD20 antibody induced significant PCD (Figures
7A and 7G).
Cytokine release and T cell proliferation are thought to be
common causes of mild and severe adverse reactions to anti-
body therapy. In order to further investigate any undesirable ef-
fects of BI-505 on ICAM-1-expressing immune cells, we there-
fore assessed putative effects of BI-505 on peripheral blood
mononuclear cells (PBMCs) cytokine release and T cell prolifer-
ation. In order tomaximize the chances of identifying any PBMC-
agonistic properties of BI-505, we used two different antibody-
coating protocols in which the antibody was hypercrosslinked
as previously described (Stebbings et al., 2007). BI-505 immobi-
lized by either protocol induced PCD in Daudi lymphoma cells,demonstrating that biological activity was retained following
immobilization (data not shown). BI-505 did not, however,
induce PBMC cytokine release and did not induce T cell prolifer-
ation by either immobilization protocol or when added in solution
in the presence or absence of crosslinking reagent (Figures 7D–
7F). In contrast and as expected, incubation of PBMCs with an
immobilized positive control anti-CD3 antibody resulted in signif-
icant release of IL-1b, IL-2, IL-6, IL-8, TNF-a, and IFN-g (Fig-
ure 7D). Analogous experiments demonstrated that BI-505
added in solution did not induce or enhance cytokine release
from resting or lipopolysaccharide prestimulated PBMCs and
did not induce T cell proliferation (Figures 7E and 7F).
Taken together therefore, we have found no evidence for un-
desirable activation or cytotoxicity of BI-505 against ICAM-1-
expressing immune cells. Together with limited safety studies
in rat, rabbit, and monkey, demonstrating no compound-related
off-target toxicity (data not shown), and indicating a long half-life
typical of that for a human IgG (i.e., 12–13 days in rat [Table S2],
corresponding to 2–3 weeks in man), these observations indi-
cated a therapeutically relevant safety profile and pharmacoki-
netics of BI-505.Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc. 509
Figure 6. BI-505 Confers Fc-FcgR-Depen-
dent Antitumor Activity through Macro-
phages
(A) Mean tumor volume of SCID mice bearing
established ARH-77 tumors and treated with iso-
type control antibody or BI-505 IgG1, BI-505 IgG4,
or BI-505 IgG1 N297Q (Fc-variant) antibodies.
*p < 0.05, **p < 0.01.
(B) BiaCore analysis of BI-505 Fc-variant anti-
bodies binding to mouse FcgRIV.
(C) BiaCore analysis of BI-505 Fc-variant anti-
bodies binding to human FcgRIIIa.
(D) Immunohistochemical quantitation of F4/80+
macrophages (top panel) or NK cells (lower panel)
in tumor tissue of animals bearing established
ARH-77 tumors treated with control antibody or
BI-505. Graphs show mean F4/80+ and NK-cell-
positive tumor areas, respectively. Bar = 40 mm.
*p < 0.05, ***p < 0.001.
(E) Tumor growth in macrophage or NK-cell-
depleted SCID mice bearing established RPMI-
8226 myeloma tumors treated with BI-505 or
control antibody. ***p < 0.001.
(F) Animal survival following BI-505 or control
antibody treatment in a disseminated NK-cell-
deficient NOD/Shi-scid/IL-2Rg/ mouse model
comprising i.v. grafted U266 myeloma cells.
***p < 0.001.
(G) Tumor growth in BI-505 or control antibody-
treated NK-cell-deficient NOD/Shi-scid/IL-2Rg/
mice transplanted with RPMI-8226 myeloma cells.
***p < 0.001.
(H) Macrophage ADCP of RPMI-8226 and OPM-2
myeloma cells. n = 4, ***p < 0.001.
(I) Macrophage-mediated ADCP of primary multi-
ple myeloma cells. n = 2, ***p < 0.001.
(J) Macrophage ADCP of ICAM-1+ EJM myeloma
cells. n = 2, ***p < 0.001.
There were eight to ten animals per treatment
group. Error bars show ± SD.
See also Figure S4 and Table S1.
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We report the successful application of a function-first approach
to therapeutic antibody discovery, resulting in the isolation of a
human ICAM-1 antibody based on its (1) specificity for a surface
receptor upregulated on tumor B cells, (2) significant tumor pro-
grammed-cell-death-inducing properties, and (3) significant
in vivo antitumor activity against human B cell tumors. Thus,
our functional screening methodology was successfully applied
both to identify a function (induction of PCD in tumor cells) of a
well-characterized receptor (ICAM-1) and a human antibody
against the same target with significant therapeutic potential.510 Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc.Our function-first approach to antibody
discovery offers several advantages over
and differs in several respects from con-
ventional approaches in which antibodies
are identified based on specificity for a
predefined target structure. By com-
bining powerful differential biopanning of
a naive human antibody library withhigh-throughput tumor cell death screening, our discovery plat-
form enables the simultaneous generation of multiple high-
affinity antibodies with therapeutic potential and specificity
for different tumor-cell-associated receptors. The value of
screening for functionality across different specificities has
been indicated by previous studies, which collectively demon-
strate that antibodies against different tumor-associated cell
surface receptors can have significant antitumor activity against
the same cancer cell type (for a review, see Cheson and Leonard
[2008]). Thus, in a highly diversified antibody source, such as
n-CoDeR, the most therapeutically efficacious, potent, and
best-tolerated antibodies with respect to a given type of cancer
Cancer Cell
ICAM-1 Antibody Has In Vivo Antimyeloma Activitycould be specific for one of several receptors, and identifying the
optimal antibodies requires functional screening of antibodies
targeting all such receptors.
The predictive value of tumor PCD as an indicator of an anti-
body’s therapeutic potential was demonstrated by the enhanced
in vivo antitumor activity of BI-505 against CD20-expressing
tumors, compared to rituximab. Cragg andGlennie (2004) further
indicate the importance of using a function-first approach and of
screening for tumor PCD. Different antibodies, which bound with
similar affinity to CD20 and had identical Fc regions, differed
greatly in their therapeutic efficacy in vivo and, intriguingly,
conferred antitumor activity by different mechanisms of action.
Superior therapeutic activity correlated positively with tumor
PCD and inversely with complement-dependent tumor cell cyto-
toxicity (Beers et al., 2008; Cragg and Glennie, 2004). These and
other observations highlight the importance of the function-first
approach to identify antibodies with therapeutic activity (Beck
et al., 2010; Gan et al., 2009; Ivanov et al., 2009). Our use of
cancer cells, which expressly targeted antigens in their true
cell surface configuration, should increase the likelihood of
identifying antibodies with specificity for functional and dis-
ease-associated receptor epitopes compared to conventional
techniques using recombinant antigen or transfected cells in
the panning process. Finally, it is generally thought that thera-
peutic targets are limited and that most might already be identi-
fied. From this perspective, it is noteworthy that our technology
can reveal functions of previously well-characterized receptors,
indicating their suitability as targets in previously unrecognized
indications and expand the ‘‘therapeutic target space.’’ Thus,
whereas the well-characterized role of ICAM-1 in inflammation
has provided the rationale for anti-ICAM-1 targeted intervention
of acute and chronic inflammatory disorders (Kavanaugh et al.,
1997; Mileski et al., 2003; Schneider et al., 1998), our findings
identify ICAM-1 as a promising target in multiple MM and
possibly oncology in a broader sense. Taken together, our func-
tion-first approach provides an effective strategy to generate
antitumor antibodies, such as BI-505.
Several observations suggest that ICAM-1 may be a suitable
target for MM immunotherapy. Strong expression of ICAM-1 is
associated with advanced disease, poor survival, and resistance
to chemotherapy (Sampaio et al., 2009; Schmidmaier et al.,
2006; Zheng et al., 2012), which is the current inevitable end-
stage of MM (Kyle and Rajkumar, 2004). Consistent with these
observations, we demonstrate that a majority of MM cells ex-
press high levels of the epitope targeted by BI-505. High and
homogenous expression on the tumor cell surface and upregu-
lated expression in conjunction with disease progression and
the development of resistance to chemotherapy are hallmarks
of targets suitable for therapy with antibodies that confer direct
tumor cell cytotoxicity. The antitumor activity of BI-505 corre-
lated with antibody binding to tumor-cell-expressed ICAM-1
and was shown to be Fc:FcgR dependent. Accumulating
evidence suggests that interactions between an antibody’s con-
stant domain (Fc) and a host’s Fc gamma receptors (FcgR) are
instrumental in the therapeutic efficacy of rituximab and other
approved anticancer antibodies (Bibeau et al., 2009; Lejeune
et al., 2008; Musolino et al., 2008; Weng and Levy, 2003; Zhang
et al., 2007) via mechanisms that may involve both innate and
adaptive immunity (Alduaij and Illidge, 2011; Park et al., 2010),as well as enhanced tumor PCD following FcgR-dependent
crosslinking of tumor bound mAb (Wilson et al., 2011). Conse-
quently, although there is currently no antibody available to treat
MM, nonclinical and clinical studies on antibodies approved
for treatment of different types of cancer suggest that those—
like BI-505—that are capable of triggering MM cell death via
Fc:FcgR-dependent immunity hold particular promise of improv-
ing MM survival. Our finding that macrophages are principal
effector cells conferring BI-505 FcgR-dependent antitumor ac-
tivity is intriguing. Macrophages are abundantly present in MM
bone marrow and accumulating data point to a detrimental role
for macrophages and ICAM-1 in MM development of drug resis-
tance (Zheng et al., 2009, 2012). BI-505 harnessing of tumor-
associated macrophages to confer antitumor activity thus
appears an attractive mechanism of combatting MM.
In addition to exerting significant antitumor activity, a thera-
peutic cancer antibody must be safe and tolerable for patients.
Previous studies by independent investigators demonstrated
that treatment with (a murine) anti-ICAM-1 antibody was well
tolerated by different patient groups (Kavanaugh et al., 1997;
Mileski et al., 2003; Schneider et al., 1998). Herein presented
data on BI-505 is consistent with this notion. Owing to its fully
human nature, and as indicated from our animal studies,
BI-505 should have low immunogenicity.
Collectively, our results demonstrate proof-of-principle for the
function-first approach in the search for efficient antitumor anti-
bodies and provide a rationale for further preclinical and clinical
evaluation of BI-505 in the treatment of MM. An open-label
multicenter phase I dose-escalation study with BI-505 in
relapsed/refractory MM patients, approved by the Swedish
Medical Product Agency and in accordance with the United
States Food and Drug Administration’s (FDA) guidance, is
ongoing (NCT01025206; http://clinicaltrials.gov/).
EXPERIMENTAL PROCEDURES
Cell Culture and In Vitro Assays
ARH-77, RPMI-8226, and Daudi cell lines were obtained from the American
Type Culture Collection (ATCC, Sweden). NCI-H929, EJM, and OPM-2 cell
lines were obtained from the Deutsche Sammlung von Mikroorganismen
und Zellkulturen (DSMZ, Germany). HUVEC and HMVEC cells were obtained
from Cascade Biologics (Portland, OR, USA). Cells were maintained in culture
media as recommended by the supplier and maintained at 37C in a 5% CO2,
95% humidity incubator. Cell PCD, ADCC, CDC, cytokine release, and T cell
proliferation assays were performed as described elsewhere (Fransson
et al., 2006; Supplemental Experimental Procedures).
Patient Cell Studies
Plasmacell surfaceexpressionof ICAM-1and theBI-505epitopewasanalyzed
by fluorescence-activated cell sorting (FACS).Bonemarrowaspirateswereob-
tained from 29 patients diagnosed with MM or related diseases at the Depart-
ment of Hematology, Ska˚nes University Hospital, Lund. All human samples
were collected using protocols approved by the Ethics Committee of Ska˚ne
University Hospital, and informed consent was obtained from all patients.
Animal Studies
Studies were conducted in accordance with guidelines of the Lund University
Hospital, Sweden, or University of Utah, Salt Lake City, USA, following
approval from the local ethical committee for animal care and use. BI-505
efficacy and potency was examined in subcutaneous and disseminated, pro-
phylactic and therapeutic, experimental MMmodels comprising myeloma cell
lines RPMI-8226, U266, EJM, and OPM-2. The in vivo efficacy of BI-505 was
compared to clinically approved drugs dexamethasone, melphalan,Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc. 511
(legend on next page)
Cancer Cell
ICAM-1 Antibody Has In Vivo Antimyeloma Activity
512 Cancer Cell 23, 502–515, April 15, 2013 ª2013 Elsevier Inc.
Cancer Cell
ICAM-1 Antibody Has In Vivo Antimyeloma Activitybortezomib, and revlimid used at clinically relevant doses in therapeutic
disseminated models comprising RPMI-8226 or primary patient myeloma
cells, the latter following injection of patient cells in implanted of human fetal
bone in SCID mice. For subcutaneous grafting, 1–5 3 106 tumor cells
(RPMI-8226, NCI-H929, EJM, OPM-2, ARH-77, or Daudi) were subcutane-
ously injected at a volume of 100 ml into the left flank of anesthetized mice
as described in the Supplemental Experimental Procedures. For established
xenograft studies, when tumors reached an average size of 80–120 mm3, an-
imals were sorted to give nearly identical group mean tumor sizes and were
treated with isotype control antibody (20 mg/kg/inj), rituximab (20 mg/kg/inj),
or BI-505 antibody (0.02 to 20 mg/kg/inj, as indicated in the text) intraperitone-
ally (i.p.) twice weekly until study termination. For disseminated experimental
models of MM, RPMI-8226 (10 3 107 tumor cells) were injected intravenously
(i.v.) into the caudal vein of anesthetized mice after whole-body irradiation (1.8
Gy, 60Co, INRA, Bretennieres). Treatment with saline, isotype control IgG,
bortezomib, lenalidomide, dexamethasone, or BI-505 started on day 5
(RPMI-8226). Treatment with melphalan started on day 10. BI-505 or isotype
IgG mAb was administered i.v. at 2 mg/kg/inj twice weekly for 8 weeks; borte-
zomib at 1 mg/kg/inj once weekly for 8 weeks; lenalidomide orally at 2 mg/kg/
inj for two cycles consisting of 5 days of treatment and 2 days of wash out;
melphalan i.v. at 3 mg/kg/inj once weekly for 8 weeks; and dexamethasone
at 6 mg/kg/inj three times weekly for 2 weeks. In vivo mechanistic studies as-
sessing the role of Fc-FcgR interactions utilized wild-type and engineered
FcgR-binding-deficient (N297Q) IgG1 variants of BI-505. The role of macro-
phages and NK cells for BI-505 in vivo antitumor activity was assessed using
anti-asialo antibody treatment, clodronate liposome treatment, or NK-cell-
deficient mice. For a detailed description of in vivo studies, see the Supple-
mental Experimental Procedures.
In Vitro Functional Studies
Peripheral blood-derived monocytes, NK cells, B cells, and T cells were puri-
fied from buffy coats from healthy donors obtained from the local blood central
at Lund University Hospital and Halmstad Hospital. Briefly, PBMCs were first
extracted using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Waukesha,
WI, USA), followed by isolation of monocytes with CD14 MicroBeads and
MACS Separation (Miltenyi Biotec, Bergisch Gladbach, Germany). Mono-
cyte-derived macrophages were generated by 6–14 days culture in the pres-
ence of 25 ng/ml of recombinant human M-CSF (R&D Systems, Minneapolis,
MN, USA). For multiple myeloma cells, freshly isolated bone marrow samples
were donated by patients at Lund University Hospital and subsequently pro-
cessed with Ficoll-Paque PLUS. Negative isolation of malignant plasma cells
was performed using Plasma Cell Isolation Kit II (Miltenyi Biotec).
ADCP
Cultured macrophages were detached and plated in flat 96-well plates at
50,000 cells/well and placed in 37C. Carboxyfluorescein succinimidyl esterFigure 7. BI-505 Does Not Induce Apoptosis, ADCC, CDC, T Cell Proli
Expressing ICAM-1
(A) Apoptosis in peripheral blood B cells. Graph shows percent live (nonapoptotic
DR (positive control IgG), or BI-505 (0, 1.5, 6, or 24 mg/ml). Values were normaliz
(B) ADCC of peripheral blood B cells. Graph shows specific lysis of target periphe
control). Values were normalized to treatment with isotype control IgG, where sp
(C) CDC of peripheral blood B cells and Daudi Burkitt’s lymphoma cells. Cells were
(D) Antibody-induced PBMC cytokine release. PBMC cytokine release was meas
TNF-a following incubation of cells in plates coated with hypercrosslinked (air-d
antibody.
(E) Antibody-induced cytokine release in lipopolysaccharide (LPS)-primed PBM
submaximal cellular release of IL-1b (100 pg/ml), IL-6 (10 pg/ml), IL-8 (10 pg/ml)
sequent experiments assessing antibody (BI-505 or control IgG) effects on cytokin
served as positive control for robust cytokine release.
(F) Antibody-induced T cell proliferation. CFSE-labeled T cells were incubated wi
culture plates by air-drying ‘‘A’’ or wet-coating ‘‘W.’’ Cells were cultured for 6 days
signals.
(G) Antibody-induced endothelial cell apoptosis. HUVEC or HMVEC endothelial c
IgG in the presence or absence of crosslinking mAb. Apoptosis was measured b
**p < 0.01, ***p < 0.001. Error bars show ± SD.
See also Figure S5; Table S2.(CFSE)-stained target cells were incubated with antibodies for up to 1 hr on
ice. After washing, the different cell solutions were added to the culture plates
containing macrophages at a ratio of 5:1 (target cells:macrophages). There-
after, the culture plates were incubated at 37C for 1–2 hr (primary patient
MM cells) or 16 hr (RPMI-8226 cells). The percentage of macrophages that
had phagocytosed tumor cells (CFSE+, CD206+) per total analyzed macro-
phages was determined following gating and acquisition of 5,000 CD206+
cells/sample.
ADCC
NK cells were isolated from purified PBMCs using positive or negative NK cell
isolation kits (Miltenyi Biotec). Target cells were harvested and incubated in
medium with or without the respective antibodies (2 mg/ml) for 60 min on ice
before. NK cells were washed, diluted in ADCC medium, and dispensed
together with the respective antibody-coated target cells at varying effector/
target cell ratios. Experiments were performed in triplicate. After incubation,
TO-PRO-3 dye and counting beads (Invitrogen, Carlsbad, CA, USA) were
added, and cells were analyzed for membrane permeabilization using flow
cytometry.
CDC
Target cells were harvested as described above (under the ADCC heading)
and incubated with antibodies at 5 mg/ml for 60 min on ice and then washed.
Human serum, normal or heat-inactivated (Sigma, Sweden), was added to
tubes, and the samples were incubated for 2 hr at 37C. After completion of
incubation, ToPo-Pro-3 (Invitrogen) was added at a final concentration of
0.3 mM, and cells were analyzed for membrane permeabilization using flow
cytometry.
Detailed Experimental Procedures, including protocols for assessment of
apoptosis in normal ICAM-1-expressing endothelial cell, T cell proliferation,
PBMC cytokine release, and receptor occupancy studies, are described in
the Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2013.02.026.
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